FDA Deferring Action on Spectrum’s ROLONTIS Application As A Result of COVID-19 Related Travel Restrictions

Goodwin
Contact

Goodwin

On Monday, Spectrum Pharmaceuticals announced that the FDA was reportedly unable to conduct its required inspections of Spectrum’s Hanmi Bioplant due to travel restrictions related to the COVID-19 pandemic, and that as a result, the FDA was deferring action on the company’s Biologics License Application for ROLONTIS (eflapegrastim) until the inspections can be completed.  President and CEO of Spectrum Joe Turgeon said that the company is “actively working with the FDA to find a way to expedite the plant inspection” and is “eager to assist the FDA in completing their assessment as soon as possible.”

 While similar inspection delays have been reported by Zosano and Intercept, we are not aware of any instances in which the FDA has deferred action on biosimilar applications due to COVID-related travel restrictions. 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.